GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gossamer Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.43−0.34 (-3.88%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-352.2%
Net margin
-351.5%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -57.7% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -72.3% | 365.3% | |
| Return on assets | – | -50.4% | -69.9% | |
| Current ratio | – | 13.51 | 2.64 | |
| Debt to equity | – | 0.09 | – | |
| Net debt to EBITDA | – | 1.97× | – | |
| Interest coverage | – | -18.5× | -15.5× | |
| Capex to revenue | – | – | 0.2% | |
| Diluted shares | – | 69M | 229M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Gossamer Bio generated $709.81M from operations and spent $2.04M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$709.81M
Used
$2.04M
Capital expenditure$2.04M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-351.5%
×Asset turnover0.20×
×Equity multiplier-5.23×
=Return on equity, FY2025365.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -351.5% | 0.20× | -5.23× | 365.3% |
| FY2024 | -49.3% | 0.37× | 6.80× | -122.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$170.37M
- Cash generatingOperating cash flow above zero-$171.27M
- Return on assets improvedROA up on the prior year-18.1% → -54.0%
- Earnings backed by cashOperating cash flow above net income-$171.27M vs -$170.37M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose6.88 → 2.64
- No dilutionShare count did not rise226M → 229M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.37 → 0.15